65,437 trials
Hyperprolactinemia
Primary: To Determine if Adjunct Aripiprazole Will Resolve or Improve Prolactin Related Hormonal Side Effects (Amenorrhea, Oligomenorrhea, Galactorrhea). — 11; 7 Participants
Stress
Primary: Difference in Perceived Stress and Stress Resilience From Enrollment to Closeout — 20.24; 19.15; 23.59; 22.49 units on a scale
Central Serous Chorioretinopathy
Primary: Complete Resolution of Subretinal Fluid — 0 participants
Metabolic Syndrome · Insulin Resistance
Primary: Baseline Adipocyte Size — 4958; 4489 square micrometers — p=.05
Burkitt's Lymphoma · Burkitt'S-like Lymphoma
Primary: Complete Remission Rate: Percentage of Participants With Complete Remission (CR) — 85 percentage of participants
Neoplasms · Neoplasm Metastasis · Pancreatic Cancer
Primary: Phase 1b: Recommended Phase 2 Dose — 300 milligrams (mg)
Raynaud's Disease · Peripheral Vascular Disease
Primary: Change From Baseline in Mean Raynaud's Condition Score (RCS) at Week 4 — 3.04; 2.90; 2.98; 3.14 units on a scale — p=0.6513
HIV
Primary: Insulin Stimulated Glucose Uptake — 7.70; 8.58 mg/min per μIU/ml — p=0.71
Malaria, Vivax
Primary: Percentage of Participants With Clinically Relevant Hemolysis. — 2.41; 1.18 Percentage of participants
Coronary Artery Disease
Primary: Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI (Based on RPS) - Primary Analysis of Sensitivity Based…
BRAF Mutant Metastatic Melanoma
Primary: Phase 1 - Safety & Recommended Phase 2 Dose (RP2D) — 60 mg
Atopic Dermatitis
Primary: Percentage of Participants Achieving the Investigator's Global Assessment (IGA) for Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 12…
Coronary Artery Disease
Primary: Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI - Primary Analysis of Sensitivity Based on Blinded…
Pain
Primary: CSF to Plasma Concentration Ratio — 0.15 Ratio
Diabetic Macular Edema · Epiretinal Membrane
Primary: Central Retinal Thickness — 350 micrometers